LONDON (Alliance News) - Pharmaceutical services company Clinigen Group PLC on Tuesday said its Idis Global Access unit has signed a supply deal with drug maker Galen Ltd.
Under the deal, Idis will provide Galen's DaunoXome chemotherapy drug to doctors on an on-demand basis in 20 European countries, Australia, New Zealand and Hong Kong.
No financial details on the agreement were disclosed.
"This is our first exclusive supply agreement since Clinigen's acquisition of Idis in 2015 and an important part of Idis GA's ongoing strategy to increase the number of product agreements to better meet patients unmet needs," said Steve Glass, Clinigen's managing director.
Clinigen shares were down 2.7% to 535.75 pence.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
